Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 6/20 | 0.46 |
| ▸ | PPARG | P37231 | 5/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.43 |
| ▸ | CTSK | P43235 | 7/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2947991 | 1.00 | PPARA (0.46) | PPARAPPARGPPARDMTNR1AMTNR1B | |
| SCHEMBL2947993 | 1.00 | PPARA (0.46) | PPARAPPARGPPARDMTNR1AMTNR1B | |
| SCHEMBL2675628 | 1.00 | PPARA (0.46) | PPARAPPARGPPARDMTNR1AMTNR1B | |
| SCHEMBL1542228 | 0.92 | PPARA (0.46) | PPARAPPARGPPARDMTNR1AMTNR1B | |
| SCHEMBL3593703 | 0.92 | PPARA (0.46) | PPARAPPARGPPARDMTNR1AMTNR1B | |
| SCHEMBL22202893 | 0.86 | CTSK (0.50) | PPARAPPARGPPARDMTNR1AMTNR1B | |
| SCHEMBL18549277 | 0.83 | PPARA (0.45) | PPARAPPARGPPARDCTSKCTSS | |
| SCHEMBL18549299 | 0.83 | PPARA (0.45) | PPARAPPARGPPARDCTSKCTSS | |
| SCHEMBL4275633 | 0.81 | ATM (0.55) | PPARAPPARGCTSKCTSSATM | |
| SCHEMBL5821214 | 0.81 | ATM (0.55) | PPARAPPARGCTSKCTSSATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3048098-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AbbVie Bahamas Limited (BS) | 2016-07-27 | — | — | EP | disclosed |
| EP-1685119-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBVIE BAHAMAS LTD (BS) | 2016-03-09 | — | — | EP | disclosed |
| US-9045444-B2 | Apoptosis promoters | ABBVIE INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140187531-A1 | APOPTOSIS PROMOTERS | ABBVIE INC. (US) | 2014-07-03 | — | — | US | disclosed |
| EP-2308812-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBVIE BAHAMAS LTD (BS) | 2014-02-26 | — | — | EP | disclosed |
| US-8614318-B2 | Apoptosis promoters | ABBVIE INC. (US) | 2013-12-24 | — | — | US | disclosed |
| US-20130190488-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2013-07-25 | — | — | US | disclosed |
| US-8354404-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2013-01-15 | — | — | US | disclosed |
| US-8173811-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2012-05-08 | — | — | US | disclosed |
| US-8084607-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2011-12-27 | — | — | US | disclosed |
| US-7504512-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2009-03-17 | — | — | US | disclosed |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | disclosed |
| US-20070015787-A1 | Apoptosis promoters | ABBVIE INC. | 2007-01-18 | — | — | US | disclosed |
| US-20060128706-A1 | Apoptosis promoters | ABBVIE INC. | 2006-06-15 | — | — | US | disclosed |
| EP-1318978-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | ABBVIE INC. | 2004-09-30 | — | — | US | disclosed |
| US-6720338-B2 | BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | disclosed |
| EP-1318978-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2003-06-18 | — | — | EP | disclosed |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | ABBVIE INC. | 2002-07-04 | — | — | US | disclosed |
| WO-2002024636-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | PPARA 2308/4885PPARG 2763/4885PPARD 3293/4885 |
| US-20060128706-A1 | Apoptosis promoters | BAX, BCL2, API5 | PPARA 2112/4885PPARG 1697/4885PPARD 3254/4885 |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | PPARA 2308/4885PPARG 2763/4885PPARD 3293/4885 |
| US-20130190488-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | PPARA 2112/4885PPARG 1697/4885PPARD 3254/4885 |
| US-20070015787-A1 | Apoptosis promoters | BAX, BCL2, API5 | PPARA 2112/4885PPARG 1697/4885PPARD 3254/4885 |
| US-20140187531-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | PPARA 2112/4885PPARG 1697/4885PPARD 3254/4885 |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | BCL2A1, BAX, BCL2L1 | PPARA 631/4885PPARG 498/4885PPARD 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.